Shanghai, China-based Rona Therapeutics announced on Friday that it has completed a $35 million Series A+ funding round.
The round was led by LongRiver Investments, with participation from investors including Zhaode Investment, BioTrack Capital, Zhongqi Capital and Lilly Asia Ventures.
LongRiver Investments, which will join Rona’s board of directors in connection with the Series A+ financing, commented, “Rona Therapeutics has successfully advanced two best-in-class siRNA metabolism programs globally, demonstrating the value of its differentiated clinical data and platform. We are impressed with the progress Rona has made in developing its innovative siRNA pipeline and expanding into extrahepatic delivery to the CNS and beyond. We look forward to partnering with the Rona team to unlock the potential of RNA medicines as transformative treatments for patients around the world.”
This article is available to registered users only. To continue reading, please sign up for free. Your free trial will give you access to one week of exclusive features, interviews, roundups and commentary from some of the sharpest minds in the pharma and biotechnology sector. If you’re already a registered user, please log in. If your trial has expired, you can sign up here.
Log in to your account
Try before you buy
free
7-day trial access
Try our free trial. We bring you all the news that matters in the world of pharma and biotech. Exclusive features, podcasts, interviews, data analysis and commentary from our global network of life sciences journalists. Receive The Pharma Letter’s daily breaking news bulletins, free forever.
Become a subscriber
£820
Or £77 per month
Subscribe now Get unlimited access to leading pharma and biotech news, commentary and analysis. Latest updates on clinical trials, conferences, M&A, licensing, funding, regulatory, patent and legal, executive appointments, commercial strategies and financial results. A daily roundup of major pharma and biotech events. An in-depth monthly briefing on executive appointments and M&A news. Choose from our cost-effective annual package or flexible monthly subscriptions. Pharma Letter is a highly useful and valuable life sciences service that brings together daily updates on performance, talent and products. It’s a vital piece of information to keep you informed.
Chairman of Sanofi-Aventis UK
Sign up to receive email updates
Get daily news from leaders in biotech and pharmaceuticals
